Haleon completes tranche: 273,737 shares bought and cancelled

Rhea-AI Filing Summary

Haleon plc announced the purchase and cancellation of 273,737 ordinary shares of each under the second tranche of its share buyback programme. The trades reported relate to executions on 11 September 2025, totaling 273,737 shares with an average price shown as 364.1267 (per the trade breakdown). After settlement, registered share capital is 8,952,377,436 ordinary shares, with 1,527,758 held in treasury, leaving 8,950,849,678 ordinary shares with voting rights. The company provided a full breakdown of individual trades via a public link and noted the announcement does not constitute an offer for securities.

Insights

Securities Analyst

TL;DR A small tranche of the announced buyback was executed; share count reduced slightly and voting shares updated for disclosure rules.

The company executed purchases of 273,737 ordinary shares under its second buyback tranche, with the aggregate trade data showing an average price of 364.1267 as published. The announcement updates the registered share capital and the number of voting shares (8,950,849,678), which shareholders should use for disclosure threshold calculations. The transaction is routine and intended to effect share cancellation under the existing programme; based on the absolute numbers reported, this single execution appears immaterial to capitalization or ownership concentration.

Corporate Governance Expert

TL;DR Governance disclosure completed correctly: buyback details, post-cancellation share counts and trade breakdown link provided.

The company followed market abuse and disclosure rules by publishing the trade breakdown and updating post-cancellation share capital and treasury holdings. The clear reporting of the number of voting shares supports compliance with investor notification thresholds. This is a standard compliance disclosure accompanying executed buybacks; the size of the purchase relative to total issued shares suggests limited governance or control impact from this tranche alone.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	12 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

12 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 273,737 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	11 September 2025	11 September 2025	11 September 2025
Number of Shares purchased:	273,737	-	-
Highest price paid per Share (p):	366.0000	-	-
Lowest price paid per Share (p):	362.0000	-	-
Volume weighted average price paid per Share (p):	364.1267	-	-

Following the settlement of the above, the Company's registered share capital is 8,952,377,436 ordinary shares of £0.01 each, of which 1,527,758 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,950,849,678 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/0419Z_1-2025-9-11.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 12, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon (HLNCF) purchase under the buyback tranche?

273,737 ordinary shares were purchased for cancellation under the second tranche of the buyback programme.

What is the company's post-settlement number of ordinary shares with voting rights?

After settlement there are 8,950,849,678 ordinary shares with voting rights.

How many treasury shares does Haleon hold after this transaction?

The company holds 1,527,758 shares as treasury shares.

Where can I find the full breakdown of individual trades for the buyback?

A full breakdown is available via the link provided in the announcement: http://www.rns-pdf.londonstockexchange.com/rns/0419Z_1-2025-9-11.pdf.

Does this announcement constitute an offer for securities?

No. The announcement states it does not constitute, or form part of, an offer or solicitation for securities.